tabersonine has been researched along with Obesity in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, P; Chen, Y; Huang, W; Liang, G; Lin, W; Luo, W; Wang, X; Wu, G; Ye, B | 1 |
| Cao, S; Chen, Y; Lin, W; Liu, M; Qian, C; Sun, X; Wang, J; Wang, Y; Wu, H; Yang, J; Zhang, M | 1 |
2 other study(ies) available for tabersonine and Obesity
| Article | Year |
|---|---|
Tabersonine alleviates obesity-induced cardiomyopathy by binding to Transforming growth factor activated kinase 1 (TAK1) and inhibiting TAK1-mediated inflammation.
Topics: Animals; Inflammation; MAP Kinase Kinase Kinases; Mice; Mice, Obese; Obesity; Transforming Growth Factors | 2023 |
Tabersonine attenuates obesity-induced renal injury via inhibiting NF-κB-mediated inflammation.
Topics: Animals; Inflammation; Kidney; Kidney Diseases; Mice; NF-kappa B; Obesity | 2023 |